549 related articles for article (PubMed ID: 29763936)
1. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling.
Sun X; Xu Y; Wang Y; Chen Q; Liu L; Bao Y
Med Sci Monit; 2018 May; 24():3193-3203. PubMed ID: 29763936
[TBL] [Abstract][Full Text] [Related]
2. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
Tang N; Zhang Q; Fang S; Han X; Wang Z
Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073
[TBL] [Abstract][Full Text] [Related]
4. [The CK2 inhibitor quninalizarin enhances the anti-proliferative effect of icotinib on EGFR-TKIs-resistant cell lines and its underlying mechanisms].
Zhou Y; Zhang S; Li K; Li QW; Zhou FZ; Li ZY; Ma H; Dong XR; Liu L; Wu G; Meng R
Zhonghua Zhong Liu Za Zhi; 2016 Feb; 38(2):100-4. PubMed ID: 26899328
[TBL] [Abstract][Full Text] [Related]
5. Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis.
Xiang M; Jiang HG; Shu Y; Chen YJ; Jin J; Zhu YM; Li MY; Wu JN; Li J
Int J Biol Sci; 2020; 16(9):1536-1550. PubMed ID: 32226300
[TBL] [Abstract][Full Text] [Related]
6. [Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer].
Wang M; Zhang L; Zhao X; Liu J; Chen Y; Wang C
Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):651-6. PubMed ID: 25564053
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib.
Wang J; Wang Y; Zheng C; Hou K; Zhang T; Qu X; Liu Y; Kang J; Hu X; Che X
Cell Biol Int; 2018 Sep; 42(10):1292-1299. PubMed ID: 29885023
[TBL] [Abstract][Full Text] [Related]
8. Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo.
Liu T; Jin L; Lu W; Gan H; Lin Z; Chen M; Liu J; Zhang F; Wang S; Zhang H; Deng W; Chen H
J Exp Clin Cancer Res; 2019 Apr; 38(1):148. PubMed ID: 30953548
[TBL] [Abstract][Full Text] [Related]
9. Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer.
Zhang T; Zheng C; Hou K; Wang J; Zhang Y; Fan Y; Zhao H; Qu X; Liu Y; Kang J; Che X; Hu X
Cell Biol Int; 2019 Feb; 43(2):98-107. PubMed ID: 29972257
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
Xia X; Liu Y; Liao Y; Guo Z; Huang C; Zhang F; Jiang L; Wang X; Liu J; Huang H
Eur J Pharmacol; 2019 Aug; 856():172409. PubMed ID: 31132355
[TBL] [Abstract][Full Text] [Related]
11. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
12. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
[TBL] [Abstract][Full Text] [Related]
13. Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines.
Li K; Zhou F; Zhou Y; Zhang S; Li Q; Li Z; Liu L; Wu G; Meng R
Int J Mol Med; 2019 Aug; 44(2):437-446. PubMed ID: 31173177
[TBL] [Abstract][Full Text] [Related]
14. Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.
Yang G; Yao Y; Zhou J; Zhao Q
Oncol Rep; 2012 Jun; 27(6):2066-72. PubMed ID: 22446631
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts.
Cui J; Zhang Y; Su D; Li T; Li Y
Thorac Cancer; 2018 Sep; 9(9):1156-1165. PubMed ID: 30047610
[TBL] [Abstract][Full Text] [Related]
16. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
[TBL] [Abstract][Full Text] [Related]
17. In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
Wang MC; Liang X; Liu ZY; Cui J; Liu Y; Jing L; Jiang LL; Ma JQ; Han LL; Guo QQ; Yang CC; Wang J; Wu T; Nan KJ; Yao Y
Oncol Rep; 2015 Jan; 33(1):239-49. PubMed ID: 25370413
[TBL] [Abstract][Full Text] [Related]
18. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
19. Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer.
Zhang Z; Lian X; Xie W; Quan J; Liao M; Wu Y; Yang ZZ; Wang G
Sci Rep; 2020 Dec; 10(1):20924. PubMed ID: 33262410
[TBL] [Abstract][Full Text] [Related]
20. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
